GlassScriptPhysician profile
George Antonopoulos
NPI 1326660069
$5,614.92
in general payments reported to CMS, 2019-2025
12 companies · $2,827 in 2025
The $2,827 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.34 · 2023: $487 · 2024: $2,279 · 2025: $2,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,534 · Travel and Lodging: $58.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,534.12 |
| Travel and Lodging | $58.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,456.81 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $1,021.54 | 2023-2025 | Diamondback Peripheral, Esprit, Supera |
| Boston Scientific Corporation | $391.33 | 2024-2025 | Varithena Administration Pack |
| Bard Peripheral Vascular, INC. | $248.81 | 2024 | Venclose Maven Catheter |
| Abbvie INC. | $130.90 | 2025 | |
| Revance Therapeutics, INC. | $93.09 | 2024 | Daxxify |
| Depuy Synthes Sales INC. | $69.62 | 2022-2025 | Orthovisc, Monovisc |
| Exact Sciences Corporation | $63.17 | 2025 | Cologuard Collection Kit |
| Teleflex LLC | $52.81 | 2025 | Pulsar-18 T3 |
| Avanos Medical | $44.95 | 2025 | Genvisc 850 Sodium Hyaluronate |
| Dexcom, INC. | $22.52 | 2025 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $19.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Antonopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.